Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

patient expectations

Effective Leadership During & After the COVID-19 Pandemic

Carol Stiff, Head of Canada at Santen, delves into what effective leadership looks like before, during, and after COVID-19; challenges brought on by the pandemic; the importance of developing partnerships...

Impetus Digital

InSite Events™ National Pharma Meeting: A Customer Story

How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online.

Impetus Digital

- PMLiVE

Merck & Co halts development of potential COVID-19 drug MK-7110

Pharma company has abandoned drug due to technical, clinical and regulatory uncertainties

- PMLiVE

Making social sexy

By Amy Johnson

- PMLiVE

McCann Health UK appoints Jonathan Kukathasan as president

Kukathasan has spent over 15 years working at McCann Health

- PMLiVE

Indigo Medical joins imc group

The addition of Indigo Medical boosts imc group’s geographic footprint and capabilities

- PMLiVE

Saturnino Izquierdo takes on expanded role at McCann Health

Izquierdo has been appointed president, Europe and Latin America (LATAM) at the healthcare comms network

- PMLiVE

From if to how: when imagination and regulation work together

By Michael Bradley

- PMLiVE

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

- PMLiVE

European Commission approves Opdivo plus Cambometyx for advanced kidney cancer

Checkpoint inhibitor plus tyrosine kinase inhibitor approved for the first-line treatment of advanced renal cell carcinoma

- PMLiVE

GSK discontinues two feladilimab trials in head and neck cancer

Decision made after recommendation from Independent Data Monitoring Committee

- PMLiVE

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

PD-1 inhibitor improved overall survival compared to chemotherapy medication docetaxel

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links